Tumours with exceptionally high ER expression likely exhibit maximal dependence on the ER signalling pathway, rendering them particularly vulnerable to the combined ER pathway and CDK4/6 inhibition [5,6]. The gene discussed is CDK4; the disease is neoplasm.